United States Value & Access
Build economic models and HEOR deliverables designed specifically for the US market. Our senior team, experienced with US payers, supports evidence generation with a deep understanding of payer expectations, market dynamics and methodological standards. We develop US-specific models, AMCP dossiers and evidence packages, so you aren't relying on global materials but have deliverables built for your US access strategy.
Publications authored by our team
Minimum years of experience of each team member
What we deliver
AMCP dossiers
Comprehensive, evidence-based dossiers, integrating clinical efficacy, safety, economic evaluations, and budget impact evidence to demonstrate your asset’s value and support US formulary and coverage decisions.
US cost-effectiveness models
Development and adaptation incorporating US healthcare costs, treatment pathways, comparators, and analytical perspectives to quantify your asset’s value and support payer coverage and reimbursement decisions.
US budget impact models
Customizable to patient or population, incorporating treatment costs, eligible populations, market uptake, and formulary scenarios to quantify financial impact and coverage decisions for health plans and IDNs.
Payer value propositions
Evidence-based and tailored to commercial, Medicare, and Medicaid payers, highlighting clinical differentiation and economic value to support formulary positioning and coverage.
ICER review support
Strategic and technical support for ICER assessments, including evidence-based responses to draft findings to strengthen your asset’s value positioning.
Payer advisory boards and insights
Targeted interactions with commercial, Medicare, and Medicaid payer stakeholders to validate value propositions, assess formulary and coverage expectations, and inform value and access strategies.
How we work
- 01
US access landscape
Assess payer segments, competitive positioning, formulary dynamics, and coverage requirements to identify key access opportunities and barriers.
- 02
Strategic evidence planning
Set out targeted roadmap for US-specific economic models, AMCP dossiers, and payer value messaging, aligned with evidence gaps and launch priorities.
- 03
Evidence development
Develop rigorous, US-specific economic models, dossiers, and payer materials, with direct senior-level expertise and comprehensive quality review.
- 04
Payer engagement and ongoing support
Provide strategic and technical support for payer inquiries, evidence updates, and ICER assessments to strengthen value positioning and support coverage decisions.
Why Frontier HEOR
US-specific, not adapted global material.
Knowledge of US payer expectations and methods
Extensive experience with payer expectations and reimbursement dynamics to deliver scientifically rigorous, payer-relevant evidence and market access strategies.
Flexible by design
We adapt to shifting timelines, evolving evidence, and changing priorities without compromising quality or strategic focus.